Understanding Oncogenes: The Genetic Drivers of Cancer
Updated: Nov 11
Medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026
Quick Answer: What is an oncogene?
An oncogene is a mutated gene that causes cancer by driving abnormal cell growth. It starts as a normal proto-oncogene that manages the cell cycle and becomes an oncogene through point mutations, gene amplification or chromosomal rearrangements. Most develop during life from environmental factors or carcinogens. [1] Identifying specific oncogenes allows targeted treatments that block cancer-driving signals.
What the research says
Targeting the BCR-ABL1 oncogene transformed leukemia care. In the IRIS trial, patients with chronic myeloid leukemia who started imatinib had an estimated 10-year overall survival of 83.3%, and 82.8% achieved a complete cytogenetic response (Hochhaus et al., N Engl J Med, 2017) [2].
Even KRAS, long called undruggable, can now be targeted. In 124 evaluable patients with KRAS G12C-mutated lung cancer, sotorasib shrank tumors in 37.1% and controlled disease in 80.6%, with median overall survival of 12.5 months (Skoulidis et al., N Engl J Med, 2021) [3].
How do proto-oncogenes turn into oncogenes?
Every human body contains trillions of cells, each governed by genes that act as instructions for growth and survival. Proto-oncogenes are the normal versions of these genes; they are responsible for driving the cell cycle, controlling how fast cells grow, and determining when a cell should naturally die through a process called apoptosis. They are essential for healthy tissue maintenance and repair.
However, when a proto-oncogene undergoes a mutation, it becomes an oncogene. In this state, the gene acts like a stuck accelerator pedal in a car, never stopping the signal for cells to grow and divide. This uncontrolled multiplication eventually leads to the formation of a mass of abnormal cells known as a tumor. While most tumors involve dozens of different mutations, a single powerful oncogene can sometimes be the primary driver of the entire disease. [1]
There are three main ways a proto-oncogene can be turned into an oncogene:
Point mutation: A small change, addition, or deletion in the DNA sequence during cell division.
Gene amplification: An abnormal increase in the number of copies of a specific gene on a chromosome. [1]
Chromosomal rearrangement: A process where pieces of chromosomes break off and swap places (translocation). [1]
What are common oncogenes and which cancers are they linked to?
Researchers have identified more than 100 different oncogenes linked to various forms of cancer. Some genes, like the Ras family, are remarkably common and are involved in approximately one in five cancers worldwide. Others are highly specific to certain organs or tissue types. Identifying which oncogene is present in a patient's tumor is a vital step in determining the most effective course of treatment.
HER2: Breast cancer.
KRAS: Pancreatic, colon, and lung cancer. [1]
EGFR: Lung adenocarcinoma.
BCR/ABL1: Chronic myeloid leukemia (CML).
CMYC: Burkitt lymphoma.
NMYC: Small cell lung cancer and neuroblastoma.
How does targeted therapy work against oncogenes?
The discovery of oncogenes has fundamentally changed the landscape of oncology. Historically, cancer treatments were broad and often affected healthy cells alongside cancerous ones. Today, targeted therapy allows providers to focus specifically on the signals sent by oncogenes. By blocking the abnormal proteins or enzymes produced by these mutated genes, doctors can stop the growth of cancer while minimizing damage to the rest of the body.
A prime example of this success is found in the treatment of chronic myelogenous leukemia (CML). This cancer is driven by the BCR-ABL oncogene. Before targeted drugs called tyrosine kinase inhibitors (TKIs) were developed, survival rates were low. Now, by specifically blocking the enzyme created by this oncogene, many patients achieve long-term remission and live significantly longer, healthier lives. [1]

How are tumor suppressor genes different from oncogenes?
Tumor suppressor genes are a separate class of genes from oncogenes, and when healthy they tell cells to stop dividing or to repair damaged DNA. While oncogenes act as the "accelerator" for cell growth, tumor suppressor genes act as the "brakes." A well-known example is the p53 gene. When these suppressor genes are healthy, they tell cells to stop dividing or to repair damaged DNA. If a tumor suppressor gene mutates and loses its function, the "brakes" fail, often working in tandem with oncogenes to accelerate the development of cancer.
Conclusion
Oncogenes are the primary engines behind many forms of cancer, but they also provide a roadmap for modern treatment. By identifying these specific genetic mutations, medical professionals can move away from one-size-fits-all approaches and toward precision medicine. As research continues to uncover new oncogenes and the triggers that cause them to mutate, the potential for even more effective and life-saving cancer therapies grows.
What steps should you take after learning about oncogenes?
If you or a loved one are facing a cancer diagnosis, ask your healthcare provider about genetic testing for your tumor. Understanding the specific oncogenes driving the condition can open the door to targeted therapies that may offer a more effective and personalized path to recovery.
Frequently Asked Questions
What is an oncogene?
An oncogene is a mutated gene that has the potential to cause cancer by triggering uncontrolled cell growth.
What is a proto-oncogene?
A normal, healthy gene that regulates cell growth but can become an oncogene if it mutates.
Are oncogenes inherited?
Most oncogenes are acquired during a person's lifetime due to environmental factors, though some genetic predispositions exist.
What triggers a gene to become an oncogene?
Factors like UV radiation, carcinogens, and certain viral infections can trigger these mutations.
How many oncogenes are there?
More than 100 different oncogenes have been linked to various types of cancer.
What is the Ras gene?
A common group of oncogenes involved in about 20% of all human cancers.
How do oncogenes cause tumors?
Oncogenes send continuous "grow" signals to cells, causing them to multiply faster than the body can manage.
What is targeted therapy?
A treatment that specifically attacks the proteins or enzymes produced by oncogenes.
Is p53 an oncogene?
No, p53 is a tumor suppressor gene, which acts as a "brake" for cell division.
What is a point mutation?
A small change in the DNA sequence that can turn a healthy gene into a cancer driver.
What is gene amplification?
A mutation where a cell makes too many copies of a specific gene.
What does "oncogenic" mean?
The term "oncogenic" literally means "causing tumor growth."
Can one oncogene cause cancer?
Yes, in some cases, a single powerful oncogene can drive the development of a tumor.
What is remission?
A state where the signs and symptoms of cancer have disappeared, often achieved through targeted therapy.
How has oncogene research improved survival?
By allowing for treatments that target the specific cause of cancer, leading to higher success rates and fewer side effects.
Medical Disclaimer
The information provided in this article is for educational purposes only and is not intended as medical advice. Always seek the guidance of a qualified healthcare professional regarding any medical condition or treatment.
Source date: February 20, 2025.
Related Reading
Tumor Suppressor Genes: The Body's Natural Defense Against Cancer explains the genes that act as brakes on cell growth.
Genetic Testing for Cancer Risk: Who Needs It, How It Works and What Results Mean covers who should consider testing for inherited cancer risk.
Targeted Therapy for Cancer: How It Works, Types, Side Effects and Outlook describes drugs that block the proteins made by oncogenes.
Genetic Mutations: Understanding the Blueprint of Human Variation explains how DNA changes happen and why some cause disease.
References
Cleveland Clinic. Oncogene: What They Are & What They Do. Cleveland Clinic. Last updated February 20, 2025. https://my.clevelandclinic.org/health/body/24949-oncogenes
Hochhaus A, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376(10):917-927. PMID 28273028. https://doi.org/10.1056/NEJMoa1609324
Skoulidis F, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021;384(25):2371-2381. PMID 34096690. https://doi.org/10.1056/NEJMoa2103695




Comments